Comparison of midazolam versus captopril in patients with uncomplicated hypertensive urgency in emergency ward: Double-blind randomized clinical trial.

IF 0.5 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS
Mohammad Reza Khorsand, Mostafa Enayatrad, Seyed Meysam Yekesadat, Maryam Khodayar, Amir Noyani
{"title":"Comparison of midazolam versus captopril in patients with uncomplicated hypertensive urgency in emergency ward: Double-blind randomized clinical trial.","authors":"Mohammad Reza Khorsand,&nbsp;Mostafa Enayatrad,&nbsp;Seyed Meysam Yekesadat,&nbsp;Maryam Khodayar,&nbsp;Amir Noyani","doi":"10.48305/arya.2022.26128","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The urgency of uncomplicated blood pressure (BP) is known as a sudden rise in BP. The aim of this study was to evaluate the intravascular administration of midazolam as an emergency care to control BP against captopril in patients with uncomplicated hypertension (HTN).</p><p><strong>Methods: </strong>The present study was a double-blind parallel randomized clinical trial (RCT) study that was performed on patients with urgent HTN referred to Imam Hossein Hospital in Shahroud, Iran, in 2018. Patients with BP higher than 180/110 mmHg and with healthy vital organs were selected randomly and allocated into three groups of 43 participants. All patients' BP in both arms, and after a period of 10 minutes in the left arm, was checked and after administering the medication was checked again for 4 times of 15 minutes till 1 hour complete.</p><p><strong>Results: </strong>There were significant differences between systolic (P = 0.024), diastolic (P = 0.001), and mean BP (P = 0.009) in the midazolam group before and after treatment. The group of midazolam and captopril showed the greatest reduction of BP before, in the middle, and after carrying out the treatment methods. As such, systolic, diastolic, and mean BP showed 23.5% (P = 0.047), 17.4% (P = 0.021), and 20.5% (P = 0.031) reduction, respectively.</p><p><strong>Conclusion: </strong>Midazolam can be used as an effective and low-risk drug for lowering BP. Midazolam also has a faster effect on lowering BP.</p>","PeriodicalId":46477,"journal":{"name":"ARYA Atherosclerosis","volume":null,"pages":null},"PeriodicalIF":0.5000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2d/01/ARYA-18-4-2379.PMC9937673.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ARYA Atherosclerosis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.48305/arya.2022.26128","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The urgency of uncomplicated blood pressure (BP) is known as a sudden rise in BP. The aim of this study was to evaluate the intravascular administration of midazolam as an emergency care to control BP against captopril in patients with uncomplicated hypertension (HTN).

Methods: The present study was a double-blind parallel randomized clinical trial (RCT) study that was performed on patients with urgent HTN referred to Imam Hossein Hospital in Shahroud, Iran, in 2018. Patients with BP higher than 180/110 mmHg and with healthy vital organs were selected randomly and allocated into three groups of 43 participants. All patients' BP in both arms, and after a period of 10 minutes in the left arm, was checked and after administering the medication was checked again for 4 times of 15 minutes till 1 hour complete.

Results: There were significant differences between systolic (P = 0.024), diastolic (P = 0.001), and mean BP (P = 0.009) in the midazolam group before and after treatment. The group of midazolam and captopril showed the greatest reduction of BP before, in the middle, and after carrying out the treatment methods. As such, systolic, diastolic, and mean BP showed 23.5% (P = 0.047), 17.4% (P = 0.021), and 20.5% (P = 0.031) reduction, respectively.

Conclusion: Midazolam can be used as an effective and low-risk drug for lowering BP. Midazolam also has a faster effect on lowering BP.

Abstract Image

Abstract Image

Abstract Image

咪达唑仑与卡托普利在急诊科无并发症高血压急症患者中的比较:双盲随机临床试验。
背景:无并发症血压(BP)的急迫性被称为血压突然升高。本研究的目的是评价血管内给药咪达唑仑对无并发症高血压(HTN)患者控制血压的紧急护理效果。方法:本研究是一项双盲平行随机临床试验(RCT)研究,研究对象是2018年在伊朗沙赫鲁德伊玛目侯赛因医院转诊的紧急HTN患者。随机选择血压高于180/110 mmHg且重要器官健康的患者分为三组,每组43人。所有患者在双臂及左臂10分钟后检查血压,给药后每15分钟再次检查4次,直至1小时完成。结果:咪达唑仑组治疗前后收缩压(P = 0.024)、舒张压(P = 0.001)、平均血压(P = 0.009)差异均有统计学意义。咪达唑仑和卡托普利组在治疗前、治疗中、治疗后血压下降幅度最大。因此,收缩压、舒张压和平均血压分别下降23.5% (P = 0.047)、17.4% (P = 0.021)和20.5% (P = 0.031)。结论:咪达唑仑是一种有效的低风险降压药物。咪达唑仑在降低血压方面也有更快的效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
ARYA Atherosclerosis
ARYA Atherosclerosis CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
1.00
自引率
0.00%
发文量
0
审稿时长
18 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信